Compare ATEC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEC | INBX |
|---|---|---|
| Founded | 1990 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2006 | 2024 |
| Metric | ATEC | INBX |
|---|---|---|
| Price | $8.92 | $97.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 3 |
| Target Price | $22.00 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 3.3M | 291.2K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.04 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $101,739,000.00 | $1,300,000.00 |
| Revenue This Year | $18.97 | N/A |
| Revenue Next Year | $16.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $6.82 | $20.55 |
| 52 Week High | $23.29 | $155.29 |
| Indicator | ATEC | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 52.00 |
| Support Level | $8.10 | $71.31 |
| Resistance Level | $13.08 | $153.14 |
| Average True Range (ATR) | 0.53 | 6.53 |
| MACD | 0.09 | 0.94 |
| Stochastic Oscillator | 60.19 | 64.29 |
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.